Chapter 16 - Therapeutic approaches of immunogenetic molecules in inflammatory bowel disease management

Abstract

Inflammatory bowel disease (IBD) is a long-term inflammatory disease that primarily affects the human digestive tract. IBD is caused by an immunological imbalance in the lining of the gut, caused primarily by the cells of the adaptive immune system that respond to self-antigens, resulting in chronic inflammation. The two predominant types of IBD include Crohn’s disease and ulcerative colitis. Both are immune-mediated gastrointestinal inflammatory diseases that cause stomach pain, rectal bleeding, diarrhea, and other symptoms. Mucosal inflammation can be treated with immunogenic drugs, and these are promising biological molecules. This chapter is focused on the current situation and new promising therapies in immunogenetics that will help address the inflammatory disease in a timely manner and help clinicians and medical professionals with the prognosis and ultimate alleviation of the symptoms in the patients in a targeted manner. In IBD therapeutics, a new era is opened up, and immunotherapy seems to be a prospective promising treatment approach.